The aim of the present study was to evaluate the activity of the NAWAlution WoundCare (R) solution on various bacteria and to determine its suitability for use in critical care units. The effect of the antiseptic solution, NAWAlution (R) WoundCare(NAWA Heilmittel GmbH, Germany) was evaluated with and without the addition of albumin, using the broth microdilution method. A total of eight gram negative, four gram positive type bacteria that may be isolated in an intensive care unit and spore-forming bacteria Bacillus spp., as well as C. albicans were studied. E. coli, K. pneumonia, E. faecium, S. aureus and ATCC strains were used in the study. In vitro cytotoxic activity of the NAWAlution WoundCare (R) antiseptic solution was determined by 3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyl tetrazolium bromide test. NAWAlution WoundCare (R) was found to be effective against K. pneumoniae at a concentration of 1/32; against A. baumanii, P. aeruginosa, Chryseobacterium spp, S. maltophilia and Shewanella at a concentration of 1/64; and against E. coli at a concentration of 1/256. However, no activity was observed against B. cepacia. The substance was effective against MRSA at a concentration of 1/64; against voncomycin-resistant E. faecium, vancomycin-sensitive E. faecium and Bacillus spp. at a concentration of 1/128; against methicillin-sensitive S. aureus and methicillin-resistant coagulase negative staphylococci at a concentration of 1/256; and against C. albicans at a concentration of 1/256. However, NAWAlution WoundCare solution at a concentration of between 1/10 and 1/2560 had no cytotoxic effect on the Vero cells. In conclusion NAWAlution WoundCare (R) antiseptic solution was found to be effective against many microorganisms that could cause wound infection, and is also appropriate for direct topical application.